Get App

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of the retina) in AIDS patients and in prevention of cytomegalovirus (CMV) disease after organ transplant.
  • Published On Nov 13, 2018 at 07:19 AM IST
<p>In 2014, Cipla signed a deal with US-based Merck to sell Isentress (raltegravir), an anti-AIDS drug in India in what the two companies described as complementary strengths of scientific excellence and marketing reach. </p>
In 2014, Cipla signed a deal with US-based Merck to sell Isentress (raltegravir), an anti-AIDS drug in India in what the two companies described as complementary strengths of scientific excellence and marketing reach.
Drug major Cipla Monday said it has received final approval from the US health regulator for Valganciclovir tablets, used in the treatment of viral eye infection in AIDS patients.

Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of the retina) in AIDS patients and in prevention of cytomegalovirus (CMV) disease after organ transplant.

Advt
The approved products is a generic therapeutic equivalent version of Roche's Valcyte.

Cipla has received approval for the product in the strength of 450 mg from the United States Food and Drug Administration (USFDA), the company said in a BSE filing.

Quoting IQVIA (IMS Health) data, Cipla said Valcyte and its generic equivalents had US sales of around USD 79 million for the 12-month period ending September 2018.

Shares of Cipla were trading 1.09 per cent higher at Rs 532.95 apiece on BSE.
  • Published On Nov 13, 2018 at 07:19 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App